Osprey Pharmaceuticals

Description

Osprey Pharmaceuticals USA (OPUS) is a clinical stage company focused on the development of novel protein therapeutics for the treatment of inflammatory and immune diseases. The company is advancing a pipeline of proprietary fusion protein therapeutics known as Leukocyte Population Modulators (LPMs) that are designed to selectively target and neutralize chemokine-activated leukocytes underlying a variety of inflammatory and immune diseases. The Company's lead candidate, CCL2-LPM targeting the CCR2 chemokine receptor expressed by certain pathologically activated leukocytes is in a Phase Ib clinical trial for the treatment of IgA nephropathy. The company has developed a powerful chemokine-based protein therapeutic platform based on our pioneering insight into the chemokine system, a complex network of chemokine molecules (ligands) and receptors that regulate cell migration and inflammatory immune responses. Each of our novel protein therapeutics is designed to target a specific chemokine receptor, thereby blocking the inappropriate immune system cascade underlying a given disease. With approximately 50 distinct chemokines identified and associated with well over 100 different clinical conditions, the LPM platform has the potential to yield a multitude of novel drugs directed at diseases which are not satisfactorily addressed with current therapeutics. To date we have created the cell lines for twelve distinct LPMs. The OPUS strategy is to demonstrate the safety and therapeutic utility of the LPM approach in patients, initially using OPL-CCL2-LPM and then a second LPM in another indication. It is the Company's intent to work closely with major pharmaceutical and biotechnology partners to develop and commercialize the approach by means of partnerships by indication or LPM. The LPM platform technology was originally developed by a co-founder, John McDonald, PhD, of Osprey Pharmaceuticals, Limited in Montreal and is subject to numerous and broad issued patents and patent applications worldwide. OPUS owns these patents and continues to fund additional research to build on this novel therapeutic approach. Recent Osprey Manuscripts -Osprey Manuscripts (PDF)

Companies nearby